Share Name Share Symbol Market Type Share ISIN Share Description
Oxford Biomedica LSE:OXB London Ordinary Share GB0006648157 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 8.75p 8.51p 8.90p - - - 0 06:30:30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 27.8 -20.3 -0.6 - 270.24

Oxford Biomedica Share Discussion Threads

Showing 100126 to 100148 of 100150 messages
Chat Pages: 4006  4005  4004  4003  4002  4001  4000  3999  3998  3997  3996  3995  Older
DateSubjectAuthorDiscuss
24/9/2017
11:03
I hope we will gather some momentum here. Please keep the informative comments coming.
city chappy
24/9/2017
08:38
HTTPS://scienceofparkinsons.com/2017/09/07/voyager-therapeutics-phase-ib-clinical-trial-results/ This sounds really fantastic. Right? Well, Prosavin was one of the success stories in the gene therapy world. But please remember that the first Prosavin study was an open-label trial. The Prosavin product really needs to be tested in a double blind study. This is particularly important because there was very little actual difference between brain scans of dopamine processing before the study started and 6 months into the study – this may be one of the reasons why the company is seeking a more potent virus. And this is one of the reasons why the Voyager Therapeutics results were so pleasing to see this week. Not only did the study find an increase in the production of AADC in the putamen, but it also provided evidence that the gene therapy approach can actually work for Parkinson’s disease.
marcusl2
23/9/2017
18:22
The result with Sheila Roy was a very special thing, and sort of vindicates your hopes for ProSavin. She is a walking ambassador for OXB, but as with all things OXB it's not straight forward. The protocol amendments mean that some patients were injected, some infused and most of these weren't at the same baseline when they started treatment. With small numbers in a dose escalation trial, changing patients and treatment methods halfway through probably wasn't the best thing to do with regard to conclusive trial results. The money for the second trial got spent on other things. ProSavin is probably our most valuable spin-out prospect as things stand today (i.e. without any unexpected results from a TroVax trial - or similar).
harry s truman
23/9/2017
18:06
I have felt for some time that lentivector and Prosavin ( I have to admit that Prosavin has always been my favorite)and maybe something will come out of blue with lentivector.
antreg
23/9/2017
17:47
It's still in there Antreg. When I wrote "With TroVax we await results", then I meant that there's always hope. But... CRC (TacTicc) seemed a "good" result, though the difference between the TroVax arm and the non TroVax arm wasn't night and day. It was an improvement and it seemed to do something, but the hope with the IRS biomarker pre-screened patients was that everybody would respond. They plainly didn't. Mesothelioma (SKOPOS) nobody has any idea as they've never said, but as various people have noted, it seems unlikely that they are hiding good news. If the result of that trial was outstandingly good, then we would probably know by now. Prostate (Vance) is a mixture of TroVax and PrimeBoost and might be the one that does it, but that won't read out anytime soon. Ovarian (Trioc) is another long term trial. Something might come of it. TroVax was why I came here. But I have to be realistic and when OXB rebranded themselves as "the lentivector company" then that doesn't include TroVax (to which they have publicly said they will spend no more money on) and there's probably a good reason for that.
harry s truman
23/9/2017
15:32
Harry I am suprised that you have now dropped Trovax from your list of expectations.
antreg
23/9/2017
14:22
Estimated Enrollment: 15 Study Start Date: December 2015 Estimated Primary Completion Date: February 2018 (Final data collection date for primary outcome measure) HTTPS://clinicaltrials.gov/ct2/show/NCT02640209 Eight of nine evaluable patients tested had no signs of CLL in their bone marrow at three months. CTL119 is a humanized CD19-directed CAR-T cell therapy being developed in collaboration with the University of Pennsylvania Novartis is committed to advancing a portfolio of next-generation CAR-T cell therapies HTTPS://www.novartis.com/news/media-releases/novartis-next-generation-car-t-cell-therapy-ctl119-combined-ibrutinib-shows-high
marcusl2
23/9/2017
09:38
Yes Prosavin and CAR T 5T4 the main hopes for me. Perhaps TRiP will produce some income also? At least Novartis` CAR Ts are likely to do very well for us. Have a nice day.
marcusl2
23/9/2017
09:13
Morning Marcus, I feel like we have been down this road before, but for RetinoStat there may be no market. Sanofi will have thought long and hard before taking the other 2 (ushstat / stargen) only. Doesn't mean that RetinoStat doesn't work or that EncorStat won't. Just that they don't see the business model working for them.Remember pram's point from the AGM about promising drugs getting dropped. It's just the business.ProSavin seems most likely to be partnered. With TroVax we await results.Anyway, have a good day.
harry s truman
23/9/2017
08:42
It really is about time JD came up with something for the in-house drugs. Any deal would be very welcome. I can`t find any details about the recent presentations. Next one; September 27 4:35pm – 5:05pm OXB Cantor Fitzgerald Healthcare Conference New York, USA
marcusl2
22/9/2017
23:33
Something we've gone on about many times in the past Marcus, but the people working in these charity funded studies do seem to work at a different pace than the commercially funded studies. Remember that SKOPOS / mesothelioma completed sometime before the TacTicc / CRC trial, but we've yet to see any kind of results with the former. With CRC they essentially gave us a half-time score followed by the full results within a quarter or so of when they said that they would report - and now we've had another bite of that cherry - but remembering there that CRC was the second of the current TroVax trials. SKOPOS is well overdue now.
harry s truman
22/9/2017
19:54
Chester youngster cancer free for a year. hTTp://www.chesterstandard.co.uk/home/2017/09/22/gallery/inspirational-chester-youngster-erin-cross-cancer-free-for-a-year-95753/
ewads
22/9/2017
17:46
That's a nice 1 million share purchase from this morning just posted now at 9.39p
beanol
22/9/2017
16:25
Good find Marcus,does this all follow on from the Trovax trial in 2012?
northstand
22/9/2017
16:01
ITV REPORT 22 September 2017 at 7:25am Breakthrough in bowel cancer treatment Scientists at Cardiff University have discovered a new way to prolong the life of people with bowel cancer. Bowel Cancer Credit: Cardiff University Researchers have completed clinical trials which involved treatment strategies to boost the power of the immune system of inpatients with end-stage bowel cancer. This early phase study, funded by Cancer Research Wales, is thought to be amongst the first immunotherapy trial in bowel cancer to show a significant improvement in survival outcomes for patients with advanced disease. 55 patients were recruited to the trial at Velindre Cancer Centre. Patients whose immune system could be boosted lived on average for 20months, compared to 10 months in those who failed to respond to the new treatments. Th study showed that patients who respond by generating immune responses to up-regulated, tumour proteins do well, and this is a fundamentally important finding. The clear benefit to patients opens the door for larger downstream immunotherapy trials which have the potential to expand future treatment options of colon cancer. – PROFESSOR ANDREW GODKIN, CONSULTANT GASTROENTEROLOGIST FROM CARDIFF UNIVERSITY, SCHOOL OF MEDICINE As bowel cancer represents the second leading cause of cancer death in Wales, this study represents a big step forward in the management of a disease that is very difficult to treat in the advanced stages. We as a charity are proud to have supported this work as we continue to seek further breakthroughs in this very exciting field of cancer treatment. – LIZ ANDREWS, CHARITY DIRECTOR OF CANCER RESEARCH WALES This early stage research is a step in the right direction for investigating new treatment options for people with advanced bowel cancer. Bowel Cancer UK would like to see further larger scale studies developed to determine how effective this approach could be in practice. This study is a testament to the exciting research which is taking place in Wales. – LOWRI GRIFFITHS, HEAD OF WALES FOR BOWEL CANCER UK Last updated Fri 22 Sep 2017
marcusl2
22/9/2017
15:21
That is his monthly director's fee Master RSI. He opted to take all his fees in shares.
prambigear
22/9/2017
14:16
DIRECTORS BUYING Dr Lorenzo Tallarigo -Chairman Friday 22 September 2017 acquired 29,685 shares @ 8.90p
master rsi
22/9/2017
13:57
Squabbles = clashing egos. And rather good entertainment as long as you are not involved ;)
wageslave
22/9/2017
12:35
City Chappy, the 'squabbles' are somewhat about what the long game will turn out to be
stocktastic
22/9/2017
11:25
The move above 9 appears to have triggered some selling but it would be very gratifying to end the day 9+
sddavies1
22/9/2017
09:35
The company seems to have finally turned the corner after a long haul. Surely that is the key point. I've never seen the point of daily posts and squabbles on discussion boards. Play the long game.
city chappy
22/9/2017
07:57
Beanol, Yes, delayed publication and looks like buys. Yesterday's ratio of buys to sells, although I know it's a long way off reliable, was very high.
small crow
21/9/2017
23:26
It looks like the late trades were posted later but occurred much earlier in the day?
beanol
Chat Pages: 4006  4005  4004  4003  4002  4001  4000  3999  3998  3997  3996  3995  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20170925 07:54:12